Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the second quarter ended June 30, 2008.

"Our strategy and focus are to develop picoplatin as an oncology platform compound addressing multiple indications, combinations and formulations. Our accomplishments during the second quarter are consistent with this objective," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are on track to commercialize picoplatin for the treatment of small cell lung cancer (SCLC) in 2010. We presented data at the American Society of Clinical Oncology (ASCO) Annual Meeting in June, illustrating the platform potential of picoplatin in multiple solid tumor indications, including metastatic colorectal cancer (CRC), hormone refractory prostate cancer (HRPC) and ovarian cancer. Data from these trials could support future trials and may be of significant interest to potential partners. We are building a comprehensive strategy to direct our clinical development plan for further development of picoplatin in a wide range of tumor types."

Second Quarter and Recent Highlights

Picoplatin Clinical Development Program

-- Small Cell Lung Cancer: Presented final data in April from our Phase 2 trial of picoplatin in SCLC at the International Association for the Study of Lung Cancer and the European Society for Medical Oncology's 1st European Lung Cancer Conference. Final efficacy results confirmed previously announced interim results showing median overall survival in the picoplatin Phase 2 trial w
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... While deep learning was the topic of many conversations ... the CEO of one start-up spoke passionately about using fast ... beyond the generally-agreed ceiling of 120 years. , Insilico Medicine, ... 12 companies recognized as the hottest GPU-powered startups in the ... Emerging Companies Summit have business models focused on self-driving ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... Bellevue, WA (PRWEB) March 27, 2015 ... it can be hard to know where to begin. ... an experienced Seattle trucking accident attorney, offers accident victims ... financial, and legal assistance to ensure their personal injury ... eBook begins by describing the first actions that should ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , KENILWORTH, N.J., Aug. 11 ... an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus ... formulations of CLARINEX(R) (desloratadine). , , ... filed and consolidated since 2006 in the U.S. District Court ...
... , Survey seeks feedback from public to help ... CHICAGO, Aug. 11 Participate in the American Dental Association (ADA) ... and become eligible to win a $150 Amazon.com gift certificate and, at the ... ADA.org provides news and information on hundreds of dental topics, ranging from ...
... , MOUNTAIN VIEW, Calif., Aug. 11 VIVUS, ... and commercialization of novel therapeutic products, today reported its financial results for the ... Second Quarter Results , , Net loss ... as compared to net income of $3.6 million, or $0.06 per share, for ...
... , , VERNON HILLS, ... provider of vascular access management services, today announced the launch ... integrated network for physicians to act as one to deliver ... new program has the potential to ultimately save money for ...
... , , SAN BERNARDINO, Calif., Aug. 11 ... food junkies, the all new comic book superhero, Super Nutricia, created by Inland ... children. This is the first ever female superhero from IEHP,s squad of masked ... (Photo: http://www.newscom.com/cgi-bin/prnh/2 0 090811/DC6 0 ...
... newborns experiencing a fatal lack of oxygen, study finds , ... there,s been a nearly 40 percent drop in the risk ... infants in Scotland, new research has found. , The major ... of deaths caused by a lack of oxygen for the ...
Cached Medicine News:Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 2Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 3Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 3Health News:VIVUS Reports Second Quarter 2009 Financial Results 4Health News:VIVUS Reports Second Quarter 2009 Financial Results 5Health News:VIVUS Reports Second Quarter 2009 Financial Results 6Health News:VIVUS Reports Second Quarter 2009 Financial Results 7Health News:Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 3Health News:Delivery-Related Infant Deaths Decline in Scotland 2
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... 2015  CCS Medical ("CCS"), one of the ... patients with chronic conditions, has named Rodney ... effective March 23.  Mr. Carson joins CCS from ... was President of Operations. Prior ... Vice President of Operations at NationsHealth, (n/k/a Convey ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8CCS Medical Team Hires Industry Operator Rodney Carson as CEO 2
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: